IL6 and episodic ataxia type 2: In the MYCOVID study, Gangneux et al. showed that the combination of anti-IL6 and dexamethasone was associated with a significantly increased risk of CAPA (HR: 2.71; 95% CI: 1.12–6.56; p = 0.027) in patients on MV [11].